Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

Integrated Epigenetic and Transcriptional Single-Cell Analysis of t(11;14) Multiple Myeloma and Its BCL2 Dependency

Noémie Leblay, Sungwoo Ahn, Rémi Tilmont, Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G Barwick, Lawrence H Boise, Nizar J Bahlis, Paola Neri

Blood blood.2023020276.

https://doi.org/10.1182/blood.2023020276

Published: 2023

Includes: Supplemental data

Journal Articles

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

Holly Lee, Paola Neri, Sungwoo Ahn, Ranjan Maity, Noemie Leblay, Bachisio Ziccheddu, Monika Chojnacka, Rémi Tilmont, Elie Barakat, Ola Landgren, Francesco Maura, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 252–253.

https://doi.org/10.1182/blood-2022-167602

Published: 2022

Journal Articles

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12997.

https://doi.org/10.1182/blood-2022-169920

Published: 2022

Journal Articles

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 604–605.

https://doi.org/10.1182/blood-2022-169721

Published: 2022

Journal Articles

CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients

Remi Tilmont, Ranjan Maity, Noemie Leblay, Holly Lee, Elie Barakat, Paola Neri, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 9964–9965.

https://doi.org/10.1182/blood-2022-169550

Published: 2022

Journal Articles

Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma

Paola Neri, Sungwoo Ahn, Holly Lee, Noemie Leblay, Mirco Friedrich, Ranjan Maity, Rémi Tilmont, Elie Barakat, Marc S Raab, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 2093–2094.

https://doi.org/10.1182/blood-2022-164717

Published: 2022

Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran

Blood (2022) 140 (Supplement 1): 10685–10686.

https://doi.org/10.1182/blood-2022-169917

Published: 2022

Journal Articles

A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma

Ranjan Maity, Sacha Benaoudia, Franz Zemp, Holly Lee, Elie Barakat, Noemie Leblay, Sungwoo Ahn, Douglas Mahoney, Paola Neri, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 327.

https://doi.org/10.1182/blood-2021-153871

Published: 2021

Journal Articles

Integrated Epigenetic and Transcriptional Single Cell Analysis of t(11;14) Myeloma and Its BCL2 Dependency

Noemie Leblay, Sungwoo Ahn, Ranjan Maity, Holly Lee, Elie Barakat, Nizar J. Bahlis, Paola Neri

Blood (2021) 138 (Supplement 1): 725.

https://doi.org/10.1182/blood-2021-152993

Published: 2021

Journal Articles

Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers

Mirco Friedrich, Paola Neri, Noemie Leblay, Niklas Kehl, Julius Michel, Holly Lee, Elie Barakat, Sungwoo Ahn, Hartmut Goldschmidt, Michael Platten, Niels Weinhold, Marc-Steffen Raab, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 731.

https://doi.org/10.1182/blood-2021-152149

Published: 2021

Journal Articles

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma

Seth Welsh, Daniel Riggs, Erin Meermeier, Chang-Xin Shi, Victoria Garbitt, Meaghen E Sharik, Megan Du, Kennedi Todd, Zachary Hammond, Sochilt Brown, Caleb K Stein, Paola Neri, Nizar J. Bahlis, Benjamin G Barwick, Larry H. Boise, W. Michael Kuehl, Marta Chesi, P. Leif Bergsagel

Blood (2021) 138 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2021-147551

Published: 2021

Journal Articles

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Fadi Towfic, María Ortiz Estévez, Philip P. Chamberlain, Kao-Tai Tsai, Erin Flynt, Marissa Hirst, Dan Rozelle, Paula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas, Anjan Thakurta

Blood (2021) 137 (2): 232–237.

https://doi.org/10.1182/blood.2020007081

Published: 2021

Includes: Supplemental data

Journal Articles

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Noemie Leblay, PhD, Ranjan Maity, PhD, Elie Barakat, Sylvia McCulloch, MD MSc, Peter Duggan, MD FRCPC, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-137650

Published: 2020

Journal Articles

Immune Deregulation in Active Multiple Myeloma

Paola Neri, MD

Blood (2020) 136 (Supplement 1): SCI5.

https://doi.org/10.1182/blood-2020-133077

Published: 2020

Journal Articles

Clonal hematopoiesis in myeloma: root of all maladies!

Paola Neri

Blood (2020) 135 (26): 2330–2331.

https://doi.org/10.1182/blood.2020005967

Published: 2020

Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 686.

https://doi.org/10.1182/blood-2019-131981

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 1793.

https://doi.org/10.1182/blood-2019-126828

Published: 2019

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

The Pandora’s box of thalidomide analogs and their substrates

Paola Neri

Blood (2019) 134 (2): 105–106.

https://doi.org/10.1182/blood.2019001420

Published: 2019

NARROW

Integrated Epigenetic and Transcriptional Single-Cell Analysis of t(11;14) Multiple Myeloma and Its BCL2 Dependency

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients

Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma

Integrated Epigenetic and Transcriptional Single Cell Analysis of t(11;14) Myeloma and Its BCL2 Dependency

Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Immune Deregulation in Active Multiple Myeloma

Clonal hematopoiesis in myeloma: root of all maladies!

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

The Pandora’s box of thalidomide analogs and their substrates

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only